nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—CYP3A4—type 2 diabetes mellitus	0.213	1	CbGaD
Salmeterol—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.0522	0.0987	CbGbCtD
Salmeterol—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.0417	0.0789	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Nateglinide—type 2 diabetes mellitus	0.0397	0.075	CbGbCtD
Salmeterol—CYP3A7—Nateglinide—type 2 diabetes mellitus	0.0397	0.075	CbGbCtD
Salmeterol—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.0378	0.0714	CbGbCtD
Salmeterol—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.0348	0.0659	CbGbCtD
Salmeterol—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.0337	0.0636	CbGbCtD
Salmeterol—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.0298	0.0563	CbGbCtD
Salmeterol—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.0274	0.0519	CbGbCtD
Salmeterol—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0238	0.0449	CbGbCtD
Salmeterol—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0212	0.04	CbGbCtD
Salmeterol—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0194	0.0366	CbGbCtD
Salmeterol—CYP3A5—Losartan—type 2 diabetes mellitus	0.0184	0.0348	CbGbCtD
Salmeterol—CYP2C8—Losartan—type 2 diabetes mellitus	0.0177	0.0334	CbGbCtD
Salmeterol—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0169	0.032	CbGbCtD
Salmeterol—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0153	0.029	CbGbCtD
Salmeterol—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0116	0.0219	CbGbCtD
Salmeterol—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0111	0.021	CbGbCtD
Salmeterol—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0111	0.021	CbGbCtD
Salmeterol—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0105	0.0199	CbGbCtD
Salmeterol—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00784	0.0148	CbGbCtD
Salmeterol—CYP3A4—Losartan—type 2 diabetes mellitus	0.00717	0.0136	CbGbCtD
Salmeterol—Arbutamine—ADRB3—type 2 diabetes mellitus	0.00166	0.456	CrCbGaD
Salmeterol—Labetalol—ADRB3—type 2 diabetes mellitus	0.00118	0.323	CrCbGaD
Salmeterol—Salbutamol—CYP3A4—type 2 diabetes mellitus	0.000335	0.0921	CrCbGaD
Salmeterol—Propafenone—CYP1A2—type 2 diabetes mellitus	0.000283	0.0777	CrCbGaD
Salmeterol—Propafenone—CYP3A4—type 2 diabetes mellitus	0.000187	0.0514	CrCbGaD
Salmeterol—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000125	0.000594	CcSEcCtD
Salmeterol—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000125	0.000594	CcSEcCtD
Salmeterol—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000125	0.000593	CcSEcCtD
Salmeterol—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000125	0.000593	CcSEcCtD
Salmeterol—Agitation—Irbesartan—type 2 diabetes mellitus	0.000124	0.000592	CcSEcCtD
Salmeterol—Hypertension—Metformin—type 2 diabetes mellitus	0.000124	0.000589	CcSEcCtD
Salmeterol—Urticaria—Glyburide—type 2 diabetes mellitus	0.000124	0.000589	CcSEcCtD
Salmeterol—Nervousness—Losartan—type 2 diabetes mellitus	0.000124	0.000589	CcSEcCtD
Salmeterol—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000124	0.000589	CcSEcCtD
Salmeterol—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000123	0.000587	CcSEcCtD
Salmeterol—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.000123	0.000587	CcSEcCtD
Salmeterol—Back pain—Losartan—type 2 diabetes mellitus	0.000123	0.000587	CcSEcCtD
Salmeterol—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000123	0.000586	CcSEcCtD
Salmeterol—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000123	0.000586	CcSEcCtD
Salmeterol—Muscle spasms—Losartan—type 2 diabetes mellitus	0.000123	0.000583	CcSEcCtD
Salmeterol—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000122	0.000582	CcSEcCtD
Salmeterol—Myalgia—Metformin—type 2 diabetes mellitus	0.000122	0.000581	CcSEcCtD
Salmeterol—Chest pain—Metformin—type 2 diabetes mellitus	0.000122	0.000581	CcSEcCtD
Salmeterol—Malaise—Irbesartan—type 2 diabetes mellitus	0.000122	0.000581	CcSEcCtD
Salmeterol—Headache—Pioglitazone—type 2 diabetes mellitus	0.000122	0.000578	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000121	0.000577	CcSEcCtD
Salmeterol—Discomfort—Metformin—type 2 diabetes mellitus	0.000121	0.000574	CcSEcCtD
Salmeterol—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000121	0.000574	CcSEcCtD
Salmeterol—Nausea—Glipizide—type 2 diabetes mellitus	0.00012	0.000572	CcSEcCtD
Salmeterol—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00012	0.000572	CcSEcCtD
Salmeterol—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.00012	0.00057	CcSEcCtD
Salmeterol—Pain—Gliclazide—type 2 diabetes mellitus	0.00012	0.00057	CcSEcCtD
Salmeterol—Constipation—Gliclazide—type 2 diabetes mellitus	0.00012	0.00057	CcSEcCtD
Salmeterol—Tremor—Losartan—type 2 diabetes mellitus	0.000119	0.000568	CcSEcCtD
Salmeterol—Rash—Glimepiride—type 2 diabetes mellitus	0.000119	0.000567	CcSEcCtD
Salmeterol—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000119	0.000567	CcSEcCtD
Salmeterol—Rash—Sitagliptin—type 2 diabetes mellitus	0.000119	0.000565	CcSEcCtD
Salmeterol—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000119	0.000565	CcSEcCtD
Salmeterol—Headache—Glimepiride—type 2 diabetes mellitus	0.000118	0.000563	CcSEcCtD
Salmeterol—Ill-defined disorder—Losartan—type 2 diabetes mellitus	0.000118	0.000563	CcSEcCtD
Salmeterol—Cough—Irbesartan—type 2 diabetes mellitus	0.000118	0.000562	CcSEcCtD
Salmeterol—Headache—Sitagliptin—type 2 diabetes mellitus	0.000118	0.000562	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000117	0.000558	CcSEcCtD
Salmeterol—Agitation—Losartan—type 2 diabetes mellitus	0.000117	0.000557	CcSEcCtD
Salmeterol—Oedema—Metformin—type 2 diabetes mellitus	0.000117	0.000557	CcSEcCtD
Salmeterol—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000117	0.000556	CcSEcCtD
Salmeterol—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000117	0.000555	CcSEcCtD
Salmeterol—Angioedema—Losartan—type 2 diabetes mellitus	0.000116	0.000554	CcSEcCtD
Salmeterol—Infection—Metformin—type 2 diabetes mellitus	0.000116	0.000554	CcSEcCtD
Salmeterol—Insomnia—Valsartan—type 2 diabetes mellitus	0.000116	0.000553	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000116	0.000551	CcSEcCtD
Salmeterol—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000115	0.000549	CcSEcCtD
Salmeterol—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000115	0.000549	CcSEcCtD
Salmeterol—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000115	0.000549	CcSEcCtD
Salmeterol—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000115	0.000549	CcSEcCtD
Salmeterol—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000115	0.000549	CcSEcCtD
Salmeterol—Insomnia—Orlistat—type 2 diabetes mellitus	0.000115	0.000547	CcSEcCtD
Salmeterol—Malaise—Losartan—type 2 diabetes mellitus	0.000115	0.000547	CcSEcCtD
Salmeterol—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000115	0.000547	CcSEcCtD
Salmeterol—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000115	0.000546	CcSEcCtD
Salmeterol—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000115	0.000546	CcSEcCtD
Salmeterol—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000115	0.000546	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000115	0.000545	CcSEcCtD
Salmeterol—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000114	0.000545	CcSEcCtD
Salmeterol—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000114	0.000543	CcSEcCtD
Salmeterol—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000114	0.000542	CcSEcCtD
Salmeterol—Skin disorder—Metformin—type 2 diabetes mellitus	0.000114	0.000541	CcSEcCtD
Salmeterol—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000113	0.00054	CcSEcCtD
Salmeterol—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000113	0.000539	CcSEcCtD
Salmeterol—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000113	0.000538	CcSEcCtD
Salmeterol—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000113	0.000537	CcSEcCtD
Salmeterol—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000113	0.000537	CcSEcCtD
Salmeterol—Palpitations—Losartan—type 2 diabetes mellitus	0.000113	0.000536	CcSEcCtD
Salmeterol—Nausea—Glimepiride—type 2 diabetes mellitus	0.000112	0.000534	CcSEcCtD
Salmeterol—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000112	0.000534	CcSEcCtD
Salmeterol—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000112	0.000533	CcSEcCtD
Salmeterol—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000112	0.000532	CcSEcCtD
Salmeterol—Asthenia—Glyburide—type 2 diabetes mellitus	0.000112	0.000532	CcSEcCtD
Salmeterol—Cough—Losartan—type 2 diabetes mellitus	0.000111	0.000529	CcSEcCtD
Salmeterol—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000111	0.000529	CcSEcCtD
Salmeterol—Fatigue—Valsartan—type 2 diabetes mellitus	0.000111	0.000528	CcSEcCtD
Salmeterol—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000111	0.000527	CcSEcCtD
Salmeterol—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000111	0.000527	CcSEcCtD
Salmeterol—Oedema—Irbesartan—type 2 diabetes mellitus	0.000111	0.000526	CcSEcCtD
Salmeterol—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000111	0.000526	CcSEcCtD
Salmeterol—Mental disorder—Ramipril—type 2 diabetes mellitus	0.00011	0.000523	CcSEcCtD
Salmeterol—Constipation—Valsartan—type 2 diabetes mellitus	0.00011	0.000523	CcSEcCtD
Salmeterol—Infection—Irbesartan—type 2 diabetes mellitus	0.00011	0.000522	CcSEcCtD
Salmeterol—Fatigue—Orlistat—type 2 diabetes mellitus	0.00011	0.000521	CcSEcCtD
Salmeterol—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000109	0.00052	CcSEcCtD
Salmeterol—Pain—Orlistat—type 2 diabetes mellitus	0.000109	0.000517	CcSEcCtD
Salmeterol—Myalgia—Losartan—type 2 diabetes mellitus	0.000109	0.000516	CcSEcCtD
Salmeterol—Chest pain—Losartan—type 2 diabetes mellitus	0.000109	0.000516	CcSEcCtD
Salmeterol—Arthralgia—Losartan—type 2 diabetes mellitus	0.000109	0.000516	CcSEcCtD
Salmeterol—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000108	0.000516	CcSEcCtD
Salmeterol—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000108	0.000516	CcSEcCtD
Salmeterol—Anxiety—Losartan—type 2 diabetes mellitus	0.000108	0.000514	CcSEcCtD
Salmeterol—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000108	0.000513	CcSEcCtD
Salmeterol—Rash—Bromocriptine—type 2 diabetes mellitus	0.000108	0.000512	CcSEcCtD
Salmeterol—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000107	0.000511	CcSEcCtD
Salmeterol—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000107	0.000511	CcSEcCtD
Salmeterol—Tension—Ramipril—type 2 diabetes mellitus	0.000107	0.00051	CcSEcCtD
Salmeterol—Discomfort—Losartan—type 2 diabetes mellitus	0.000107	0.00051	CcSEcCtD
Salmeterol—Headache—Bromocriptine—type 2 diabetes mellitus	0.000107	0.000508	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000107	0.000508	CcSEcCtD
Salmeterol—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000107	0.000508	CcSEcCtD
Salmeterol—Nervousness—Ramipril—type 2 diabetes mellitus	0.000106	0.000505	CcSEcCtD
Salmeterol—Dry mouth—Losartan—type 2 diabetes mellitus	0.000106	0.000505	CcSEcCtD
Salmeterol—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000105	0.0005	CcSEcCtD
Salmeterol—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000105	0.0005	CcSEcCtD
Salmeterol—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000105	0.0005	CcSEcCtD
Salmeterol—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000105	0.000498	CcSEcCtD
Salmeterol—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000104	0.000497	CcSEcCtD
Salmeterol—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000104	0.000495	CcSEcCtD
Salmeterol—Oedema—Losartan—type 2 diabetes mellitus	0.000104	0.000495	CcSEcCtD
Salmeterol—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000104	0.000494	CcSEcCtD
Salmeterol—Infection—Losartan—type 2 diabetes mellitus	0.000103	0.000492	CcSEcCtD
Salmeterol—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000103	0.000491	CcSEcCtD
Salmeterol—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000103	0.000491	CcSEcCtD
Salmeterol—Tremor—Ramipril—type 2 diabetes mellitus	0.000102	0.000487	CcSEcCtD
Salmeterol—Urticaria—Valsartan—type 2 diabetes mellitus	0.000102	0.000486	CcSEcCtD
Salmeterol—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000102	0.000485	CcSEcCtD
Salmeterol—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000102	0.000484	CcSEcCtD
Salmeterol—Tachycardia—Losartan—type 2 diabetes mellitus	0.000102	0.000483	CcSEcCtD
Salmeterol—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	0.000101	0.000482	CcSEcCtD
Salmeterol—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000101	0.000482	CcSEcCtD
Salmeterol—Fatigue—Metformin—type 2 diabetes mellitus	0.000101	0.00048	CcSEcCtD
Salmeterol—Urticaria—Orlistat—type 2 diabetes mellitus	0.000101	0.00048	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000101	0.000479	CcSEcCtD
Salmeterol—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.0001	0.000478	CcSEcCtD
Salmeterol—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.0001	0.000478	CcSEcCtD
Salmeterol—Asthenia—Gliclazide—type 2 diabetes mellitus	0.0001	0.000478	CcSEcCtD
Salmeterol—Agitation—Ramipril—type 2 diabetes mellitus	0.0001	0.000478	CcSEcCtD
Salmeterol—Constipation—Metformin—type 2 diabetes mellitus	0.0001	0.000477	CcSEcCtD
Salmeterol—Angioedema—Ramipril—type 2 diabetes mellitus	9.99e-05	0.000475	CcSEcCtD
Salmeterol—Paraesthesia—Irbesartan—type 2 diabetes mellitus	9.93e-05	0.000472	CcSEcCtD
Salmeterol—Vomiting—Glyburide—type 2 diabetes mellitus	9.91e-05	0.000472	CcSEcCtD
Salmeterol—Malaise—Ramipril—type 2 diabetes mellitus	9.86e-05	0.000469	CcSEcCtD
Salmeterol—Dyspnoea—Irbesartan—type 2 diabetes mellitus	9.85e-05	0.000469	CcSEcCtD
Salmeterol—Rash—Glyburide—type 2 diabetes mellitus	9.83e-05	0.000468	CcSEcCtD
Salmeterol—Dermatitis—Glyburide—type 2 diabetes mellitus	9.82e-05	0.000467	CcSEcCtD
Salmeterol—Headache—Glyburide—type 2 diabetes mellitus	9.77e-05	0.000465	CcSEcCtD
Salmeterol—Dyspepsia—Irbesartan—type 2 diabetes mellitus	9.73e-05	0.000463	CcSEcCtD
Salmeterol—Palpitations—Ramipril—type 2 diabetes mellitus	9.66e-05	0.000459	CcSEcCtD
Salmeterol—Feeling abnormal—Metformin—type 2 diabetes mellitus	9.65e-05	0.000459	CcSEcCtD
Salmeterol—Diarrhoea—Gliclazide—type 2 diabetes mellitus	9.58e-05	0.000456	CcSEcCtD
Salmeterol—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	9.58e-05	0.000456	CcSEcCtD
Salmeterol—Cough—Ramipril—type 2 diabetes mellitus	9.54e-05	0.000454	CcSEcCtD
Salmeterol—Fatigue—Irbesartan—type 2 diabetes mellitus	9.53e-05	0.000453	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	9.48e-05	0.000451	CcSEcCtD
Salmeterol—Hypersensitivity—Valsartan—type 2 diabetes mellitus	9.48e-05	0.000451	CcSEcCtD
Salmeterol—Constipation—Irbesartan—type 2 diabetes mellitus	9.45e-05	0.00045	CcSEcCtD
Salmeterol—Pain—Irbesartan—type 2 diabetes mellitus	9.45e-05	0.00045	CcSEcCtD
Salmeterol—Insomnia—Losartan—type 2 diabetes mellitus	9.41e-05	0.000448	CcSEcCtD
Salmeterol—Hypersensitivity—Orlistat—type 2 diabetes mellitus	9.36e-05	0.000445	CcSEcCtD
Salmeterol—Paraesthesia—Losartan—type 2 diabetes mellitus	9.34e-05	0.000444	CcSEcCtD
Salmeterol—Urticaria—Metformin—type 2 diabetes mellitus	9.31e-05	0.000443	CcSEcCtD
Salmeterol—Arthralgia—Ramipril—type 2 diabetes mellitus	9.3e-05	0.000443	CcSEcCtD
Salmeterol—Myalgia—Ramipril—type 2 diabetes mellitus	9.3e-05	0.000443	CcSEcCtD
Salmeterol—Chest pain—Ramipril—type 2 diabetes mellitus	9.3e-05	0.000443	CcSEcCtD
Salmeterol—Dyspnoea—Losartan—type 2 diabetes mellitus	9.27e-05	0.000441	CcSEcCtD
Salmeterol—Anxiety—Ramipril—type 2 diabetes mellitus	9.27e-05	0.000441	CcSEcCtD
Salmeterol—Nausea—Glyburide—type 2 diabetes mellitus	9.26e-05	0.000441	CcSEcCtD
Salmeterol—Abdominal pain—Metformin—type 2 diabetes mellitus	9.26e-05	0.000441	CcSEcCtD
Salmeterol—Dizziness—Gliclazide—type 2 diabetes mellitus	9.26e-05	0.00044	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	9.24e-05	0.00044	CcSEcCtD
Salmeterol—Asthenia—Valsartan—type 2 diabetes mellitus	9.23e-05	0.000439	CcSEcCtD
Salmeterol—Discomfort—Ramipril—type 2 diabetes mellitus	9.19e-05	0.000437	CcSEcCtD
Salmeterol—Dyspepsia—Losartan—type 2 diabetes mellitus	9.16e-05	0.000436	CcSEcCtD
Salmeterol—Asthenia—Orlistat—type 2 diabetes mellitus	9.12e-05	0.000434	CcSEcCtD
Salmeterol—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	9.11e-05	0.000433	CcSEcCtD
Salmeterol—Dry mouth—Ramipril—type 2 diabetes mellitus	9.1e-05	0.000433	CcSEcCtD
Salmeterol—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	9.04e-05	0.00043	CcSEcCtD
Salmeterol—Fatigue—Losartan—type 2 diabetes mellitus	8.97e-05	0.000427	CcSEcCtD
Salmeterol—Oedema—Ramipril—type 2 diabetes mellitus	8.92e-05	0.000424	CcSEcCtD
Salmeterol—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	8.92e-05	0.000424	CcSEcCtD
Salmeterol—Vomiting—Gliclazide—type 2 diabetes mellitus	8.9e-05	0.000423	CcSEcCtD
Salmeterol—Pain—Losartan—type 2 diabetes mellitus	8.9e-05	0.000423	CcSEcCtD
Salmeterol—Constipation—Losartan—type 2 diabetes mellitus	8.9e-05	0.000423	CcSEcCtD
Salmeterol—Rash—Gliclazide—type 2 diabetes mellitus	8.83e-05	0.00042	CcSEcCtD
Salmeterol—Dermatitis—Gliclazide—type 2 diabetes mellitus	8.82e-05	0.00042	CcSEcCtD
Salmeterol—Diarrhoea—Valsartan—type 2 diabetes mellitus	8.8e-05	0.000419	CcSEcCtD
Salmeterol—Urticaria—Irbesartan—type 2 diabetes mellitus	8.78e-05	0.000418	CcSEcCtD
Salmeterol—Headache—Gliclazide—type 2 diabetes mellitus	8.77e-05	0.000417	CcSEcCtD
Salmeterol—Nervous system disorder—Ramipril—type 2 diabetes mellitus	8.75e-05	0.000416	CcSEcCtD
Salmeterol—Abdominal pain—Irbesartan—type 2 diabetes mellitus	8.74e-05	0.000416	CcSEcCtD
Salmeterol—Body temperature increased—Irbesartan—type 2 diabetes mellitus	8.74e-05	0.000416	CcSEcCtD
Salmeterol—Tachycardia—Ramipril—type 2 diabetes mellitus	8.71e-05	0.000414	CcSEcCtD
Salmeterol—Diarrhoea—Orlistat—type 2 diabetes mellitus	8.7e-05	0.000414	CcSEcCtD
Salmeterol—Skin disorder—Ramipril—type 2 diabetes mellitus	8.66e-05	0.000412	CcSEcCtD
Salmeterol—Feeling abnormal—Losartan—type 2 diabetes mellitus	8.57e-05	0.000408	CcSEcCtD
Salmeterol—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	8.51e-05	0.000405	CcSEcCtD
Salmeterol—Dizziness—Valsartan—type 2 diabetes mellitus	8.51e-05	0.000405	CcSEcCtD
Salmeterol—Dizziness—Orlistat—type 2 diabetes mellitus	8.4e-05	0.0004	CcSEcCtD
Salmeterol—Asthenia—Metformin—type 2 diabetes mellitus	8.4e-05	0.0004	CcSEcCtD
Salmeterol—Nausea—Gliclazide—type 2 diabetes mellitus	8.32e-05	0.000396	CcSEcCtD
Salmeterol—Urticaria—Losartan—type 2 diabetes mellitus	8.26e-05	0.000393	CcSEcCtD
Salmeterol—Body temperature increased—Losartan—type 2 diabetes mellitus	8.22e-05	0.000391	CcSEcCtD
Salmeterol—Abdominal pain—Losartan—type 2 diabetes mellitus	8.22e-05	0.000391	CcSEcCtD
Salmeterol—Vomiting—Valsartan—type 2 diabetes mellitus	8.18e-05	0.000389	CcSEcCtD
Salmeterol—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	8.14e-05	0.000387	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	8.13e-05	0.000387	CcSEcCtD
Salmeterol—Rash—Valsartan—type 2 diabetes mellitus	8.11e-05	0.000386	CcSEcCtD
Salmeterol—Dermatitis—Valsartan—type 2 diabetes mellitus	8.1e-05	0.000385	CcSEcCtD
Salmeterol—Vomiting—Orlistat—type 2 diabetes mellitus	8.08e-05	0.000384	CcSEcCtD
Salmeterol—Insomnia—Ramipril—type 2 diabetes mellitus	8.07e-05	0.000384	CcSEcCtD
Salmeterol—Headache—Valsartan—type 2 diabetes mellitus	8.06e-05	0.000383	CcSEcCtD
Salmeterol—Diarrhoea—Metformin—type 2 diabetes mellitus	8.01e-05	0.000381	CcSEcCtD
Salmeterol—Rash—Orlistat—type 2 diabetes mellitus	8.01e-05	0.000381	CcSEcCtD
Salmeterol—Paraesthesia—Ramipril—type 2 diabetes mellitus	8.01e-05	0.000381	CcSEcCtD
Salmeterol—Dermatitis—Orlistat—type 2 diabetes mellitus	8.01e-05	0.000381	CcSEcCtD
Salmeterol—Headache—Orlistat—type 2 diabetes mellitus	7.96e-05	0.000379	CcSEcCtD
Salmeterol—Dyspnoea—Ramipril—type 2 diabetes mellitus	7.95e-05	0.000378	CcSEcCtD
Salmeterol—Asthenia—Irbesartan—type 2 diabetes mellitus	7.93e-05	0.000377	CcSEcCtD
Salmeterol—Dyspepsia—Ramipril—type 2 diabetes mellitus	7.85e-05	0.000374	CcSEcCtD
Salmeterol—Dizziness—Metformin—type 2 diabetes mellitus	7.75e-05	0.000368	CcSEcCtD
Salmeterol—Fatigue—Ramipril—type 2 diabetes mellitus	7.69e-05	0.000366	CcSEcCtD
Salmeterol—Hypersensitivity—Losartan—type 2 diabetes mellitus	7.66e-05	0.000365	CcSEcCtD
Salmeterol—Nausea—Valsartan—type 2 diabetes mellitus	7.64e-05	0.000363	CcSEcCtD
Salmeterol—Constipation—Ramipril—type 2 diabetes mellitus	7.63e-05	0.000363	CcSEcCtD
Salmeterol—Diarrhoea—Irbesartan—type 2 diabetes mellitus	7.56e-05	0.00036	CcSEcCtD
Salmeterol—Nausea—Orlistat—type 2 diabetes mellitus	7.55e-05	0.000359	CcSEcCtD
Salmeterol—Asthenia—Losartan—type 2 diabetes mellitus	7.46e-05	0.000355	CcSEcCtD
Salmeterol—Vomiting—Metformin—type 2 diabetes mellitus	7.45e-05	0.000354	CcSEcCtD
Salmeterol—Rash—Metformin—type 2 diabetes mellitus	7.39e-05	0.000351	CcSEcCtD
Salmeterol—Dermatitis—Metformin—type 2 diabetes mellitus	7.38e-05	0.000351	CcSEcCtD
Salmeterol—Feeling abnormal—Ramipril—type 2 diabetes mellitus	7.35e-05	0.00035	CcSEcCtD
Salmeterol—Headache—Metformin—type 2 diabetes mellitus	7.34e-05	0.000349	CcSEcCtD
Salmeterol—Dizziness—Irbesartan—type 2 diabetes mellitus	7.31e-05	0.000348	CcSEcCtD
Salmeterol—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	7.29e-05	0.000347	CcSEcCtD
Salmeterol—Diarrhoea—Losartan—type 2 diabetes mellitus	7.12e-05	0.000339	CcSEcCtD
Salmeterol—Urticaria—Ramipril—type 2 diabetes mellitus	7.09e-05	0.000337	CcSEcCtD
Salmeterol—Abdominal pain—Ramipril—type 2 diabetes mellitus	7.05e-05	0.000335	CcSEcCtD
Salmeterol—Body temperature increased—Ramipril—type 2 diabetes mellitus	7.05e-05	0.000335	CcSEcCtD
Salmeterol—Vomiting—Irbesartan—type 2 diabetes mellitus	7.03e-05	0.000334	CcSEcCtD
Salmeterol—Rash—Irbesartan—type 2 diabetes mellitus	6.97e-05	0.000332	CcSEcCtD
Salmeterol—Dermatitis—Irbesartan—type 2 diabetes mellitus	6.96e-05	0.000331	CcSEcCtD
Salmeterol—Nausea—Metformin—type 2 diabetes mellitus	6.96e-05	0.000331	CcSEcCtD
Salmeterol—Headache—Irbesartan—type 2 diabetes mellitus	6.92e-05	0.000329	CcSEcCtD
Salmeterol—Dizziness—Losartan—type 2 diabetes mellitus	6.88e-05	0.000327	CcSEcCtD
Salmeterol—Vomiting—Losartan—type 2 diabetes mellitus	6.61e-05	0.000315	CcSEcCtD
Salmeterol—Hypersensitivity—Ramipril—type 2 diabetes mellitus	6.57e-05	0.000313	CcSEcCtD
Salmeterol—Nausea—Irbesartan—type 2 diabetes mellitus	6.57e-05	0.000312	CcSEcCtD
Salmeterol—Rash—Losartan—type 2 diabetes mellitus	6.56e-05	0.000312	CcSEcCtD
Salmeterol—Dermatitis—Losartan—type 2 diabetes mellitus	6.55e-05	0.000312	CcSEcCtD
Salmeterol—Headache—Losartan—type 2 diabetes mellitus	6.52e-05	0.00031	CcSEcCtD
Salmeterol—Asthenia—Ramipril—type 2 diabetes mellitus	6.4e-05	0.000304	CcSEcCtD
Salmeterol—Nausea—Losartan—type 2 diabetes mellitus	6.18e-05	0.000294	CcSEcCtD
Salmeterol—Diarrhoea—Ramipril—type 2 diabetes mellitus	6.1e-05	0.00029	CcSEcCtD
Salmeterol—Dizziness—Ramipril—type 2 diabetes mellitus	5.9e-05	0.000281	CcSEcCtD
Salmeterol—Vomiting—Ramipril—type 2 diabetes mellitus	5.67e-05	0.00027	CcSEcCtD
Salmeterol—Rash—Ramipril—type 2 diabetes mellitus	5.62e-05	0.000268	CcSEcCtD
Salmeterol—Dermatitis—Ramipril—type 2 diabetes mellitus	5.62e-05	0.000267	CcSEcCtD
Salmeterol—Headache—Ramipril—type 2 diabetes mellitus	5.59e-05	0.000266	CcSEcCtD
Salmeterol—Nausea—Ramipril—type 2 diabetes mellitus	5.3e-05	0.000252	CcSEcCtD
Salmeterol—CYP3A5—Metabolism—HBA1—type 2 diabetes mellitus	1.17e-05	0.000261	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—LIPC—type 2 diabetes mellitus	1.17e-05	0.000261	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GCK—type 2 diabetes mellitus	1.17e-05	0.000261	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.16e-05	0.00026	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	1.16e-05	0.000259	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP11A1—type 2 diabetes mellitus	1.16e-05	0.000259	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	1.15e-05	0.000256	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SLC9A1—type 2 diabetes mellitus	1.14e-05	0.000254	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GLP1R—type 2 diabetes mellitus	1.13e-05	0.000253	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.13e-05	0.000253	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CETP—type 2 diabetes mellitus	1.13e-05	0.000251	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	1.1e-05	0.000245	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	1.1e-05	0.000245	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.1e-05	0.000245	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.09e-05	0.000244	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.08e-05	0.000242	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GNB3—type 2 diabetes mellitus	1.08e-05	0.000242	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GCG—type 2 diabetes mellitus	1.08e-05	0.000241	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.08e-05	0.000241	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—HMOX1—type 2 diabetes mellitus	1.08e-05	0.000241	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CAT—type 2 diabetes mellitus	1.06e-05	0.000237	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.06e-05	0.000237	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	1.06e-05	0.000237	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	1.06e-05	0.000237	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	1.06e-05	0.000237	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	1.06e-05	0.000237	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	1.06e-05	0.000237	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC2A2—type 2 diabetes mellitus	1.06e-05	0.000236	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.06e-05	0.000236	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SREBF1—type 2 diabetes mellitus	1.05e-05	0.000234	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PSMD6—type 2 diabetes mellitus	1.05e-05	0.000234	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SNAP25—type 2 diabetes mellitus	1.05e-05	0.000234	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CPT1A—type 2 diabetes mellitus	1.04e-05	0.000232	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—MTR—type 2 diabetes mellitus	1.04e-05	0.000232	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—APOB—type 2 diabetes mellitus	1.03e-05	0.00023	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CTGF—type 2 diabetes mellitus	1.03e-05	0.000229	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	1.03e-05	0.000229	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HMGCR—type 2 diabetes mellitus	1.02e-05	0.000227	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NAMPT—type 2 diabetes mellitus	1.02e-05	0.000227	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	1.01e-05	0.000226	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HBA1—type 2 diabetes mellitus	1.01e-05	0.000226	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GCK—type 2 diabetes mellitus	1.01e-05	0.000226	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—LIPC—type 2 diabetes mellitus	1.01e-05	0.000226	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.01e-05	0.000225	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP11A1—type 2 diabetes mellitus	1e-05	0.000224	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTM1—type 2 diabetes mellitus	1e-05	0.000224	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ADRA2A—type 2 diabetes mellitus	9.96e-06	0.000223	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	9.9e-06	0.000221	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	9.89e-06	0.000221	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC9A1—type 2 diabetes mellitus	9.86e-06	0.00022	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—LPL—type 2 diabetes mellitus	9.84e-06	0.00022	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CETP—type 2 diabetes mellitus	9.74e-06	0.000218	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	9.69e-06	0.000216	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	9.69e-06	0.000216	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ADCY5—type 2 diabetes mellitus	9.64e-06	0.000215	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GPX1—type 2 diabetes mellitus	9.6e-06	0.000215	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP2E1—type 2 diabetes mellitus	9.57e-06	0.000214	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP1A2—type 2 diabetes mellitus	9.46e-06	0.000211	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SLC2A1—type 2 diabetes mellitus	9.46e-06	0.000211	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	9.44e-06	0.000211	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	9.37e-06	0.000209	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CD36—type 2 diabetes mellitus	9.35e-06	0.000209	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GNB3—type 2 diabetes mellitus	9.28e-06	0.000207	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PPP2CA—type 2 diabetes mellitus	9.24e-06	0.000206	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP3A4—type 2 diabetes mellitus	9.22e-06	0.000206	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AVP—type 2 diabetes mellitus	9.15e-06	0.000205	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MMP3—type 2 diabetes mellitus	9.15e-06	0.000205	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IGF2—type 2 diabetes mellitus	9.11e-06	0.000204	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	9.09e-06	0.000203	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	9.07e-06	0.000203	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SLC2A4—type 2 diabetes mellitus	9.07e-06	0.000203	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GCG—type 2 diabetes mellitus	9.07e-06	0.000203	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PSMD6—type 2 diabetes mellitus	9.06e-06	0.000202	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SNAP25—type 2 diabetes mellitus	9.06e-06	0.000202	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SREBF1—type 2 diabetes mellitus	9.06e-06	0.000202	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	9e-06	0.000201	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	9e-06	0.000201	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	9e-06	0.000201	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	8.98e-06	0.000201	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CTGF—type 2 diabetes mellitus	8.89e-06	0.000199	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—MTHFR—type 2 diabetes mellitus	8.86e-06	0.000198	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APOB—type 2 diabetes mellitus	8.85e-06	0.000198	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HMGCR—type 2 diabetes mellitus	8.81e-06	0.000197	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	8.81e-06	0.000197	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EDN1—type 2 diabetes mellitus	8.71e-06	0.000195	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PPARA—type 2 diabetes mellitus	8.7e-06	0.000194	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	8.69e-06	0.000194	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	8.63e-06	0.000193	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	8.63e-06	0.000193	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ADRA2A—type 2 diabetes mellitus	8.62e-06	0.000193	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LPL—type 2 diabetes mellitus	8.45e-06	0.000189	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AGT—type 2 diabetes mellitus	8.42e-06	0.000188	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	8.31e-06	0.000186	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	8.31e-06	0.000186	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2E1—type 2 diabetes mellitus	8.29e-06	0.000185	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CALM1—type 2 diabetes mellitus	8.28e-06	0.000185	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.27e-06	0.000185	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—APOE—type 2 diabetes mellitus	8.25e-06	0.000184	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP1A2—type 2 diabetes mellitus	8.19e-06	0.000183	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC2A1—type 2 diabetes mellitus	8.19e-06	0.000183	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	8.16e-06	0.000182	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—APOA1—type 2 diabetes mellitus	8.16e-06	0.000182	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	8.03e-06	0.000179	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	8.03e-06	0.000179	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	8.03e-06	0.000179	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP3A4—type 2 diabetes mellitus	7.99e-06	0.000179	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	7.95e-06	0.000178	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	7.93e-06	0.000177	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GCG—type 2 diabetes mellitus	7.85e-06	0.000176	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC2A4—type 2 diabetes mellitus	7.85e-06	0.000176	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GNB3—type 2 diabetes mellitus	7.82e-06	0.000175	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PPARGC1A—type 2 diabetes mellitus	7.82e-06	0.000175	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCR5—type 2 diabetes mellitus	7.78e-06	0.000174	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HMOX1—type 2 diabetes mellitus	7.78e-06	0.000174	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CAT—type 2 diabetes mellitus	7.68e-06	0.000172	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—C3—type 2 diabetes mellitus	7.61e-06	0.00017	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	7.55e-06	0.000169	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—APOB—type 2 diabetes mellitus	7.45e-06	0.000167	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.25e-06	0.000162	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTM1—type 2 diabetes mellitus	7.25e-06	0.000162	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.24e-06	0.000162	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AGT—type 2 diabetes mellitus	7.23e-06	0.000162	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PPARG—type 2 diabetes mellitus	7.19e-06	0.000161	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—LPL—type 2 diabetes mellitus	7.12e-06	0.000159	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.11e-06	0.000159	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LEP—type 2 diabetes mellitus	7.08e-06	0.000158	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APOE—type 2 diabetes mellitus	7.08e-06	0.000158	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	7.07e-06	0.000158	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—INS—type 2 diabetes mellitus	7.05e-06	0.000158	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APOA1—type 2 diabetes mellitus	7e-06	0.000156	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ADCY5—type 2 diabetes mellitus	6.97e-06	0.000156	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GPX1—type 2 diabetes mellitus	6.94e-06	0.000155	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	6.82e-06	0.000153	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	6.82e-06	0.000153	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	6.82e-06	0.000153	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	6.82e-06	0.000153	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GNB3—type 2 diabetes mellitus	6.77e-06	0.000151	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.77e-06	0.000151	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CD36—type 2 diabetes mellitus	6.76e-06	0.000151	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HMOX1—type 2 diabetes mellitus	6.74e-06	0.000151	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.68e-06	0.000149	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PPP2CA—type 2 diabetes mellitus	6.68e-06	0.000149	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CAT—type 2 diabetes mellitus	6.65e-06	0.000149	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	6.54e-06	0.000146	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ALB—type 2 diabetes mellitus	6.46e-06	0.000144	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—APOB—type 2 diabetes mellitus	6.45e-06	0.000144	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—MTHFR—type 2 diabetes mellitus	6.41e-06	0.000143	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.32e-06	0.000141	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PPARA—type 2 diabetes mellitus	6.29e-06	0.000141	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTM1—type 2 diabetes mellitus	6.28e-06	0.00014	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NOS3—type 2 diabetes mellitus	6.18e-06	0.000138	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3R1—type 2 diabetes mellitus	6.18e-06	0.000138	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—LPL—type 2 diabetes mellitus	6.16e-06	0.000138	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AGT—type 2 diabetes mellitus	6.09e-06	0.000136	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	6.08e-06	0.000136	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—INS—type 2 diabetes mellitus	6.05e-06	0.000135	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ADCY5—type 2 diabetes mellitus	6.03e-06	0.000135	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GPX1—type 2 diabetes mellitus	6.01e-06	0.000134	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CALM1—type 2 diabetes mellitus	5.99e-06	0.000134	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—APOE—type 2 diabetes mellitus	5.96e-06	0.000133	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.95e-06	0.000133	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—APOA1—type 2 diabetes mellitus	5.9e-06	0.000132	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CD36—type 2 diabetes mellitus	5.86e-06	0.000131	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.85e-06	0.000131	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.85e-06	0.000131	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.82e-06	0.00013	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PPP2CA—type 2 diabetes mellitus	5.78e-06	0.000129	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	5.68e-06	0.000127	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTGS2—type 2 diabetes mellitus	5.65e-06	0.000126	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	5.56e-06	0.000124	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	5.56e-06	0.000124	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.56e-06	0.000124	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—MTHFR—type 2 diabetes mellitus	5.55e-06	0.000124	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	5.46e-06	0.000122	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PPARA—type 2 diabetes mellitus	5.44e-06	0.000122	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	5.42e-06	0.000121	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	5.42e-06	0.000121	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	5.42e-06	0.000121	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	5.39e-06	0.00012	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.31e-06	0.000119	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.31e-06	0.000119	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	5.29e-06	0.000118	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	5.27e-06	0.000118	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	5.23e-06	0.000117	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	5.2e-06	0.000116	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	5.18e-06	0.000116	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	5.17e-06	0.000115	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	5.11e-06	0.000114	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	5.1e-06	0.000114	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RELA—type 2 diabetes mellitus	4.99e-06	0.000112	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	4.86e-06	0.000109	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	4.86e-06	0.000109	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	4.86e-06	0.000109	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	4.77e-06	0.000107	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	4.73e-06	0.000106	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	4.67e-06	0.000104	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	4.63e-06	0.000103	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.55e-06	0.000102	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.5e-06	0.000101	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	4.5e-06	0.000101	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.48e-06	0.0001	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	4.47e-06	9.99e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	4.47e-06	9.99e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	4.45e-06	9.94e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	4.41e-06	9.87e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	4.4e-06	9.83e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	4.4e-06	9.83e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.26e-06	9.51e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	4.22e-06	9.42e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	4.22e-06	9.42e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.21e-06	9.41e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.13e-06	9.23e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	4.09e-06	9.14e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	4.05e-06	9.04e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SRC—type 2 diabetes mellitus	3.92e-06	8.77e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	3.87e-06	8.65e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	3.87e-06	8.65e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.82e-06	8.54e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	3.63e-06	8.12e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.63e-06	8.12e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	3.62e-06	8.09e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	3.57e-06	7.98e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	3.54e-06	7.91e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.51e-06	7.84e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	3.46e-06	7.74e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.44e-06	7.69e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	3.37e-06	7.53e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	3.31e-06	7.39e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	3.24e-06	7.24e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	3.23e-06	7.21e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	3.14e-06	7.03e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	3.1e-06	6.94e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	2.98e-06	6.66e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	2.92e-06	6.53e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AKT1—type 2 diabetes mellitus	2.84e-06	6.35e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	2.83e-06	6.33e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	2.78e-06	6.22e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	2.77e-06	6.2e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	2.74e-06	6.13e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL6—type 2 diabetes mellitus	2.64e-06	5.91e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.44e-06	5.45e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	2.42e-06	5.4e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.37e-06	5.3e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.17e-06	4.85e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.08e-06	4.64e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.08e-06	4.64e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	2.05e-06	4.59e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	1.9e-06	4.25e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	1.78e-06	3.98e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	9.55e-07	2.13e-05	CbGpPWpGaD
